阿尔茨海默病中的微质调节:神经炎症和病变发生的核心参与者
Md Sadique Hussain1, Yumna Khan2, Rabab Fatima3
1Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun 248007, Uttarakhand, India.
Current Alzheimer research
|February 20, 2025
概括
微质功能障碍通过损害粉样蛋白清除和促进病理来加剧阿尔茨海默病 (AD). 针对这些大脑免疫细胞提供治疗潜力,但面临诸如副作用和可访问性等挑战.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样β斑块和神经纤维状结.
- 微质细胞,大脑的常驻免疫细胞,在AD病变发生过程中起着至关重要的作用.
- 微质功能障碍越来越被认为是AD中神经炎症和神经退行症的关键因素.
研究的目的:
- 审查微质在阿尔茨海默病中的多方面的作用,重点关注它们对神经炎症的贡献.
- 探索微质功能障碍如何影响粉样蛋白β细胞化和高酸化.
- 讨论当前和潜在的治疗策略,针对AD治疗的微质细胞.
主要方法:
- 关于研究AD中微质的作用的研究文献综述.
- 分析分子机制,包括TREM2,影响AD中的微质功能.
- 旨在调节微质活动的治疗干预措施的评估.
主要成果:
- 微质功能障碍通过阻碍粉样β清除和促进高酸化,加剧了AD病理.
- TREM2和其他分子因素显著影响微质细胞的行为和AD的进展.
- 功能性微质细胞可能具有神经保护作用,而功能障碍的微质细胞则加速神经退行.
结论:
- 微质是AD的核心参与者,它们的功能状态决定了神经保护性或神经退行性结果.
- 准微质来减少神经炎症是阿尔茨海默病的有希望的治疗途径.
- 进一步的研究对于克服副作用,成本和有效的基于微质细胞的治疗方法的可访问性等挑战至关重要.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:47Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions
Published on: July 26, 2024
1.8K
相关概念视频
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
